EQT Leads $152M Round for Vaderis Therapeutics' Rare Disease Drug

Vaderis Therapeutics has secured a substantial $152 million Series B financing, with a significant $17.5 million investment from EQT Life Sciences. This capital infusion is earmarked to advance engasertib, a novel therapeutic candidate, through pivotal Phase 3 clinical trials. The drug is being developed as a potential first-in-class treatment for hereditary hemorrhagic telangiectasia (HHT), a debilitating rare genetic disorder affecting blood vessels.

The financing round, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, saw robust participation from a syndicate of prominent investors including Omega Funds, Perceptive Advisors, Kalehua Capital, and existing backers Medicxi and Droia. This broad support underscores the significant unmet medical need in HHT and the perceived potential of engasertib to address it.

HHT, estimated to affect approximately 1 in 3,800 individuals, is characterized by severe, recurrent nosebleeds, chronic anemia, and the risk of life-threatening vascular abnormalities. Currently, no approved therapies exist to treat the underlying condition, leaving patients with limited management options. The initiation of the global Phase 3 HEROIC study marks a critical step towards potentially offering the first targeted therapy for this patient population.

EQT Life Sciences, known for its expertise in guiding biotechnology firms through late-stage development, will actively collaborate with the Vaderis Therapeutics management team. Their involvement aims to leverage EQT's experience in navigating complex clinical pathways and regulatory submissions, supporting the company through to potential market approval. Christoph Broja, CFA, Partner at EQT Life Sciences, will join the Vaderis board as an observer, signaling a hands-on approach.

Positive proof-of-concept and long-term extension data for engasertib, published in The New England Journal of Medicine, demonstrated clinically meaningful and sustained improvements in HHT patients. These findings provided the scientific validation necessary to propel the drug into pivotal development. The $152 million raised is expected to provide Vaderis with sufficient runway to potentially achieve regulatory approval for engasertib.

Azmi Nabulsi, MD, MPH, President and Chief Executive Officer of Vaderis Therapeutics, highlighted the significance of this milestone for HHT patients, stating, "Today represents a defining moment for HHT patients." He emphasized the collaborative effort of patients, researchers, and advocacy groups, alongside the crucial support from investors, in reaching this pivotal stage. The initiation of the HEROIC study signifies a new era in HHT research, focusing on a molecule specifically designed for the condition.

The successful closure of this Series B round positions Vaderis Therapeutics as a key player in the rare disease therapeutic space. The substantial capital raised, coupled with the strategic backing of leading life science investors, provides a strong foundation for advancing engasertib and addressing a critical gap in the treatment of HHT. This development is indicative of the continued investor appetite for innovative therapies targeting underserved patient populations within the biotechnology sector.